recent
success
use
protect
monoclon
antibodi
lifesav
treatment
ebola
virusinfect
highlight
need
develop
new
technolog
fast
effici
elicit
function
monoclon
antibodi
mab
control
emerg
infecti
diseas
dna
immun
exist
today
pioneer
earli
initi
use
vaccin
platform
gener
great
excit
due
overal
simplic
use
dna
plasmid
deliv
one
particularli
attract
featur
dna
vaccin
immunogen
produc
vivo
give
abil
induc
tcell
immun
respons
endogen
antigen
process
present
pathway
howev
applic
dna
immun
human
vaccin
develop
encount
challeng
specif
low
immunogen
identifi
earli
clinic
studi
dna
vaccin
deliv
via
tradit
needl
inject
without
use
adjuv
type
deliveri
instrument
recent
year
signific
progress
made
applic
dna
vaccin
human
via
two
strategi
use
physic
deliveri
method
gene
gun
electropor
greatli
improv
immunogen
dna
vaccin
human
ii
develop
heterolog
primeboost
host
first
immun
dna
vaccin
follow
boost
immun
either
recombin
protein
antigen
tradit
kill
live
attenu
effect
homolog
primeboost
immun
use
multipl
dose
recombin
protein
tradit
time
gener
agre
dna
immun
effect
small
anim
model
use
product
highqual
mab
howev
earli
anim
model
studi
focus
mainli
tcell
immun
respons
given
uniqu
advantag
dna
immun
induc
littl
attent
paid
valu
dna
immun
elicit
highqual
antibodi
respons
much
less
given
potenti
dna
immun
induc
highqual
bcell
respons
use
product
function
mab
current
review
provid
comprehens
summari
literatur
accumul
past
two
decad
includ
work
use
dna
immun
produc
highli
function
mab
particular
emerg
infecti
diseas
dna
immun
use
tradit
approach
gener
mab
difficult
target
especi
membran
protein
vivo
immunogen
express
featur
dna
vaccin
offer
number
benefit
tradit
proteinbas
immun
approach
difficulti
produc
fulllength
protein
immunogen
recombin
protein
method
protein
natur
express
membraneassoci
format
multitransmembran
gprotein
coupl
receptor
gpcr
ion
channel
dna
immun
approach
circumv
problem
fulllength
protein
express
vivo
deliv
form
dna
vaccin
furthermor
well
known
structur
integr
protein
critic
induct
function
mab
yet
sensit
structur
tend
lost
vitro
protein
product
process
regardless
whether
produc
recombin
protein
extract
directli
cell
sourc
protein
natur
express
product
function
activ
mab
highli
depend
conform
protein
express
intact
immunogen
vivo
dna
immun
appear
best
chanc
induc
mab
desir
biolog
activ
dna
vaccin
possess
uniqu
advantag
immunogen
design
flexibl
immunogen
insert
express
fulllength
sequenc
target
protein
commonli
use
type
protein
especi
transmembran
protein
good
intracellular
protein
one
may
assum
necessari
redirect
intracellular
protein
secretori
pathway
ad
signal
peptid
elicit
better
antibodi
respons
howev
number
mab
product
studi
nativ
protein
use
dna
vaccin
immunogen
insert
without
sequenc
hand
gene
sequenc
immunogen
insert
dna
vaccin
easili
edit
express
design
protein
singletransmembran
protein
extracellular
domain
secretori
protein
select
clone
immunogen
insert
object
gener
mab
epitop
extracellular
approach
also
appli
bacteri
toxin
exampl
truncat
fragment
use
immun
place
fulllength
potenti
lethal
toxin
protein
therebi
avoid
introduct
unwant
biolog
activ
product
dna
vaccin
well
anim
addit
immunogen
manipul
includ
product
minigen
insert
express
short
peptid
sequenc
cover
receptorbind
case
antigen
determin
angiotensinconvert
enzym
bind
domain
sever
acut
respiratori
syndrom
spike
protein
close
match
coronavirus
predict
use
softwar
protean
induc
antispik
protein
antibodi
altern
transmembran
anchor
sequenc
ad
nonmembraneassoci
simpl
flexibl
immunogen
design
approach
dna
immun
offer
wide
rang
option
produc
novel
immunogen
insert
induct
mab
even
challeng
target
tabl
one
uniqu
featur
dna
immun
conveni
use
dna
vaccin
construct
express
antigen
mab
screen
choic
reagent
method
depend
origin
type
protein
tabl
cellassoci
antigenbas
screen
wide
success
use
mab
target
transmembran
protein
viral
envelop
protein
intracellular
protein
case
cell
express
immunogen
use
without
need
protein
purif
screen
bind
activ
mab
either
fluorescenceactiv
cell
sort
whole
cell
enzymelink
immunosorb
assay
elisa
immunohistochemistri
ihc
one
studi
novel
incel
western
screen
method
develop
optim
gener
monoclon
antibodi
nuclear
cytoplasm
transmembran
two
decad
effort
mani
research
group
design
commonli
use
dna
vaccin
vector
significantli
optim
establish
promot
region
dna
vaccin
vector
critic
element
function
promot
enhanc
associ
regulatori
compon
exampl
intron
sequenc
associ
cytomegaloviru
cmv
promot
significantli
enhanc
function
cmv
select
polya
tail
also
import
optim
codon
usag
particularli
import
dna
vaccin
express
gene
infecti
pathogen
often
employ
differ
codon
usag
mammalian
protein
one
area
less
studi
whether
sustain
immunogen
express
vivo
major
impact
induct
highqual
mab
one
studi
antibodi
gener
via
intraven
deliveri
plasmid
rel
efficaci
cmv
promot
human
ubiquitin
c
promot
compar
use
luciferas
model
immunogen
use
ubiquitin
promot
lead
sustain
antigen
express
liver
result
signific
level
antibodi
titer
seven
week
singl
hydrodynam
tail
vein
htv
deliveri
contrast
singl
htv
deliveri
cmv
promot
result
shortterm
antigen
express
produc
low
antibodi
titer
time
frame
nevertheless
promot
enabl
high
antibodi
titer
deliv
repeatedli
thu
studi
author
conclud
choic
express
vector
may
reduc
number
genet
immun
still
promot
induct
hightit
antigenspecif
antibodi
similarli
immun
respons
compar
employ
dna
vaccin
plasmid
encod
multidrug
resist
protein
transport
differ
promot
cmv
earli
enhancerchicken
beta
actin
promot
strong
synthet
promot
frequent
use
constitut
drive
high
level
gene
express
mammalian
express
vector
classic
cmv
promot
transient
immunogen
result
show
chicken
beta
actin
promot
induc
higher
antigenspecif
immun
respons
htv
deliveri
even
plasmid
inject
less
frequent
compar
use
cmv
promotercontain
plasmid
sinc
earli
discoveri
dna
immun
wide
rang
deliveri
approach
studi
approach
divid
two
main
categori
one
tradit
needl
inject
dna
plasmid
variou
solut
addit
facilit
agent
lipid
nanoparticl
includ
solut
enhanc
deliveri
efficaci
composit
chemic
solut
determin
uptak
efficaci
dna
vaccin
plasmid
second
deliveri
type
base
physic
forc
repres
approach
use
gene
gun
use
ballist
forc
deliv
dna
plasmid
first
dna
plasmid
coupl
gold
particl
deliv
ballist
forc
penetr
cell
target
tissu
earli
gener
gene
gun
creat
ballist
forc
ad
highvoltag
electr
drop
recent
gener
gene
gun
base
releas
compress
anoth
physic
method
dna
deliveri
use
electropor
approach
dna
vaccin
first
deliv
needl
inject
follow
applic
electr
current
dna
inject
site
rel
immunogen
chemic
physic
deliveri
approach
well
analyz
one
studi
shown
electropor
deliveri
follow
intraderm
needl
inject
effect
deliv
dna
vaccin
multipl
intracellular
compart
transmembran
cytoplasm
nucleu
lead
success
induct
anoth
studi
show
electropor
follow
intramuscular
needl
inject
gener
higher
antibodi
respons
intramuscular
needl
inject
alon
approach
also
effect
intramuscular
needl
inject
alon
dna
vaccin
formul
chemic
polym
protein
complet
analysi
compar
deliveri
dna
vaccin
intramuscular
needl
inject
electropor
follow
intramuscular
needl
inject
gene
gun
alon
shown
gene
gun
electropor
deliveri
effect
tradit
intramuscular
needl
inject
elicit
higher
antibodi
respons
gene
gun
electropor
approach
effect
gene
gun
approach
requir
microgram
dna
plasmid
achiev
level
immun
respons
elicit
electropor
approach
requir
least
dna
plasmid
first
step
intramuscular
inject
even
mice
one
interest
find
literatur
although
deliveri
approach
may
critic
induct
highlevel
immun
respons
human
vaccin
develop
differ
dna
deliveri
approach
similarli
success
produc
mab
wide
rang
target
antigen
tabl
list
mab
elicit
gene
gun
approach
needl
inject
includ
inject
electropor
follow
intramuscular
intraderm
one
uniqu
lessstudi
approach
hydrodynam
intraven
deliveri
one
larg
studi
compar
rel
immunogen
htv
hydrodynam
limb
vein
deliveri
method
differ
antigen
includ
differ
type
target
antigen
intracellular
transmembran
secretori
method
success
hydrodynam
limb
vein
deliveri
method
especi
potent
gener
antibodi
wide
rang
howev
hydrodynam
intraven
method
may
suitabl
larger
anim
rat
rabbit
given
larger
vein
size
host
compar
mice
htv
method
also
use
success
gener
mab
transport
challeng
target
mab
also
report
produc
mab
singl
intrasplen
author
gener
hybridoma
fuse
spleen
cell
day
singl
intrasplen
inject
dna
vaccin
plasmid
highest
number
specif
hybridoma
gener
day
singl
initi
howev
mab
appear
use
immunoblot
addit
studi
conduct
character
affin
optim
deliveri
schedul
induct
highqual
mab
dna
immun
remain
determin
classic
vaccin
literatur
would
indic
extend
time
period
long
rest
interv
may
effect
elicit
highqual
antibodi
respons
immun
quick
success
rel
studi
focus
sole
optim
deliveri
schedul
rather
deliveri
approach
exampl
clear
whether
physic
deliveri
approach
gene
gun
electropor
use
frequent
chemic
deliveri
approach
needl
inject
former
effect
latter
anim
studi
gener
mab
requir
multipl
immun
usual
everi
week
howev
faster
immun
procedur
report
deliv
immun
within
day
multipl
site
gene
studi
lymph
node
use
fusion
h
last
inject
without
need
final
boost
mab
gener
use
fluorescenceactiv
cell
sort
western
blot
analysi
enzymelink
immunosorb
assay
studi
need
optim
dna
immun
schedul
elicit
highqual
mab
import
determin
whether
differ
dna
deliveri
approach
optim
certain
deliveri
schedul
whether
deliveri
schedul
appli
differ
anim
speci
due
low
immunogen
dna
vaccin
earli
human
studi
great
effort
devot
inclus
variou
adjuv
part
dna
vaccin
formul
immun
studi
wide
report
literatur
follow
section
review
use
molecular
adjuv
context
mab
induct
adjuv
identifi
previou
vaccin
develop
like
use
induct
mab
addit
dedic
studi
need
confirm
actual
increment
benefit
particularli
dna
vaccin
deliveri
optim
discuss
escherichia
coli
chaperon
protein
groel
demonstr
act
potent
molecular
adjuv
dna
immun
shown
enhanc
ab
respons
gpcr
difficult
target
mab
author
report
dna
immun
mice
plasmid
encod
fulllength
endothelin
receptor
etar
fuse
groel
c
terminu
induc
strong
specif
antibodi
respons
nativ
etar
coinject
plasmid
express
etar
groel
etargroel
induc
lower
antibodi
respons
plasmid
contrast
specif
antibodi
respons
produc
mice
immun
author
also
mention
strategi
success
appli
gpcr
target
suggest
groel
capabl
produc
antibodi
gpcr
one
caution
rais
author
case
unstabl
gpcr
coimmun
groel
may
prefer
fusion
groel
induc
antibodi
respons
fusion
carrier
protein
decreas
express
function
mab
differ
gpcr
target
chemocentryx
chemokin
receptor
ccxckr
gener
coimmun
plasmid
encod
groel
dna
vaccin
plasmidencod
anoth
studi
complic
immun
strategi
test
plasmid
encod
fetal
liver
tyrosin
kinas
ligand
deliv
prime
dose
follow
codeliveri
plasmid
encod
granulocytemacrophag
colonystimul
factor
anoth
plasmid
encod
immunogen
studi
demonstr
addit
fetal
liver
tyrosin
kinas
ligand
granulocytemacrophag
colonystimul
factor
immun
modul
significantli
improv
overal
immun
respons
mice
also
induct
antibodi
capabl
recogn
nativ
extracellular
one
approach
present
great
advantag
induct
hightit
highqual
antibodi
respons
heterolog
primeboost
approach
approach
dna
vaccin
deliv
prime
immun
follow
boost
protein
antigen
recombin
protein
peptid
tradit
inactiv
live
attenu
vaccin
one
unexpect
find
regard
dna
prime
immun
abil
induc
higherlevel
antigenspecif
bcell
research
group
shown
dna
primer
immun
effect
protein
immun
activ
germin
center
b
cell
higher
level
antigenspecif
b
cell
set
stage
robust
antibodi
respons
whether
higherlevel
activ
b
cell
lead
better
mab
clone
remain
determin
dna
primeprotein
boost
approach
use
gener
mab
mous
rabbit
model
approach
effect
gener
panel
mab
protect
clostridium
difficil
toxin
challeng
well
mab
use
sensit
reagent
detect
toxin
variou
test
also
report
use
dna
immun
gener
rabbit
mab
high
affin
divers
epitopebind
profil
human
immunodefici
viru
type
envelop
one
uniqu
rabbit
mab
target
area
envelop
protein
block
bind
anoth
research
group
use
similar
dna
primeprotein
boost
approach
gener
higher
antibodi
titer
higher
qualiti
mab
observ
protein
immun
product
mab
tradit
hybridoma
method
requir
avail
mani
activ
antigenspecif
b
cell
lymphoid
organ
fusion
tradit
protein
immun
approach
achiev
final
intraven
intraperiton
inject
day
fusion
procedur
may
also
need
dna
immun
hybridoma
fusion
use
cell
dnaimmun
anim
host
without
final
boost
report
sever
howev
overal
fusion
effici
low
result
antibodi
low
bind
affin
igm
domin
isotyp
one
studi
compar
abil
final
protein
boost
final
protein
boost
respect
hybridoma
gener
conclud
despit
signific
antibodi
respons
immun
anim
fusion
mous
spleen
cell
yield
low
number
lowqual
hybridoma
unless
mice
given
boost
day
studi
includ
addit
dna
plasmid
immun
intramuscular
intraderm
inject
day
fusion
final
although
number
mab
gener
small
mab
fusion
mab
good
bind
affin
divers
final
dna
plasmid
boost
could
also
deliv
hydrodynam
inject
five
day
fusion
specif
mab
success
includ
difficult
target
multitransmembran
protein
commonli
use
final
boost
reagent
purifi
protein
use
success
final
protein
boost
secretori
intracellular
singletransmembran
protein
glycophosphatidylinositolanchor
protein
purifi
extracellular
domain
use
final
boost
confirm
protein
retain
nativ
furthermor
cell
express
antigen
protein
use
directli
final
boost
approach
success
membran
intracellular
use
cell
boost
reagent
work
secretori
protein
difficult
purifi
ad
glycophosphatidylinositol
anchor
case
viral
antigen
inact
viral
particl
use
success
final
tabl
provid
summari
final
boost
immun
option
dna
immun
use
gener
mab
either
tradit
hybridoma
approach
singl
bcell
clone
approach
differ
anim
model
research
group
recent
produc
mab
human
volunt
immun
via
hiv
vaccin
dna
primeprotein
boost
regimen
use
singl
bcell
clone
method
paper
prepar
result
show
dna
immun
use
wide
rang
host
produc
highqual
mab
dna
immun
power
approach
produc
highqual
mab
offer
sever
uniqu
advantag
dna
immun
effici
method
test
differ
immunogen
design
ii
dna
immun
requir
product
purif
protein
pathogen
avoid
issu
relat
biosafeti
iii
dna
immun
allow
rapid
respons
emerg
infecti
agent
pathogen
gene
sequenc
known
iv
dna
immun
effect
gener
mab
conformationsensit
target
v
dna
immun
use
mab
induct
wide
rang
host
includ
mous
rabbit
human
